Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Anyone pick up any rumours today?
This drop feels a bit unnatural.
Representing another good buy opportunity in my opinion
Adding
HD, most British shares these days are equally disappointing IME. In a wasteland of gloom I have very few stellar performers. Despite a few rare trading opportunities my head remains pushed just beneath the waves. Like you I shall hold on and wait for the life boat to arrive.
Stop sitting on the fence HumptyDumpty, it wont end well for you, perhaps shares in Shell might be more up your street? :)
My god this company is frustrating. It's one of those shares I keep thinking will get there eventually, but it just doesn't and in the meantime I'm losing profits that could be made elsewhere. I just can't bring myself to sell though. That continual (and long repeated) hope of a bid just keeps me here. Please someone make a bid so I can get out!!!
I would. Remember the share price was above £18 not so long ago. Was way below the worst of the COVID dip just last year ….. and just keeps crawling up a bit before dropping back again. Company needs a kick up the backside.
I hope I’m proved wrong of course!
Company hit revenue and increased profit margin... how can you call for the CEO's head.
Market games being played with the share price yes, but my strategy here is measured in years not hours.
I wonder if you'd call for the CEO's head if the 4.5% from this morning held.
Completely agree with Mulder - CEO is just not up to the job. All the earlier gains from this morning are lost after a decent Q4 report - what is going on here!
Such a positive update by share price is down. I was hoping for at least a 4-5% rise today but it’s gone down instead!
Very disappointing that the rise has once again been sold into. CEO needs to go IMO.
Soames has also disappointed so far.
Get the company sold.
No shorts listed but this has been shorted today IMO.
Momentum with SN. lol hope you all trimmed? I did not and am adding.
I'm happy. Revenue ahead of guidance, profits up and above all solid FCF and increased EPS. Positive outlook for year ahead. Orthopaedics business on the up. What's not to like? We're in for a good year of SP recovery and growth imho
Yes, I'm pleasantly surprised. Now let's hope we can build some momentum...
Market has reacted positively. Seems to be breaking out nicely.
Underwhelmed... Think we might see a dip :(
I sold out last year because I was sick of hearing about this 12 point plan and lost patience with this CEO.
He has had enough time now to turn things around so I'm expecting a good update here... If not he will be under big pressure.
Let's see what tomorrow brings. GL all!!
Look how well Stryker is doing.
The FTSE is well and truly rigged to the downside, manipulated to the max - why are boards not disclosing takeover bids?
SN must have been approached.
Well overdue a rally - during the year adding and trimming knoocked a couple of 3 of the carrying cost average but let's not give up that effort tomorrow please.
CEO is on his last chance here.
I have been out of this for nearly a year (the SP is pretty much the same as 12 months ago!) but I decided to buy back in this morning - looking for a positive update and break out in the SP.
GL all.
Place your bets? Swing high swing low?
Either way LT £18-£20
Results may move SP at end Feb
Up 20% trim down 20% add - add & trim no brainers to lower averages.
(Sharecast News) - RBC Capital Markets has reiterated its 'outperform' rating on Smith & Nephew ahead of the medical devices giant's fourth-quarter results later this month, saying it sees upside risk to current estimates.
Strong results from sector peers like Johnson & Johnson, Stryker and Zimmer Biomet suggest that the global hip and knee market expanded by a combined 7.1% in the fourth quarter, as surgery levels increased on the back of a "a return to normal phasing and secular growth in demand", RBC said.
"If Smith & Nephew's Ortho revenues have grown in line with the market, this implies up to 1% upside to Q4 group sales vs RBCe/consensus, or more if it takes share."
Meanwhile, Stryker and Zimmer Biomet also provided strong guidance for 2024 that was ahead of consensus forecasts on both revenues and profits, which could bode well for Smith & Nephew, RBC said.
"We think there is a meaningful chance that management guides to 5-7% growth in FY2024, implying c1% upside to consensus at the midpoint. Higher revenue growth would de-risk consensus forecasts for trading margin (currently 18.4%), which depends largely on operating leverage on volumes," the broker said.
Smith & Nephew's shares have underperformed the wider sector by 10% so far in 2024, which could reflect "nervousness" around hitting margin guidance, RBC said. So the reaction to a strong fourth-quarter result could be strong.
"We also remain bullish on SN in the longer term, and continue to believe its valuation vs peers does not account for its competitive positioning or growth outlook."
The broker has a 1,500p target price for the stock, which was up 0.3% at 1,096p by 0855 GMT.
Hardman & Co
Smith & Nephew (SN.) has, generally, been a weak performer in 2023. Although there was an uplift in the shares following the reporting of 2022 results, the stock faced corrections after reporting 1Q’23 and 1H’23 results, since when there has been a modest recovery. I am surprised that the perennial (every year for >30 years!!) acquisition rumours did not re-ignite when it hit its low point in October.